Biofluid‐based biomarkers to predict onset of Alzheimer's disease neuropathology

Abstract

Biofluid‐based biomarkers detect amyloid, tau and neurodegeneration (ATN) pathophysiological changes prior to onset of symptoms. But are there biomarkers that can predict the onset of these pathologies, i.e., predict AD before the brain changes have developed?